EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 8371 participants.
Also called NCT06531824
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 8,371 participants
- Sponsor
- Registry
-
NCT06531824 -
2024-511025-63-00 -
U1111-1306-5049
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, China, Denmark, Germany, India, Italy, Japan, Malaysia, Mexico, New Zealand, Portugal, South Korea, Sweden, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06531824. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-30 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- Condition
- Kidney Disease, Chronic
- Intervention (Drug)
- BI 690517
- Intervention (Drug)
- Placebo matching BI 690517
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06531824- Content hash
38e30be3b4829b7af63c9e6ff9324f2bcc9d674533252c3fd0dadbfc5c202e41